肝细胞肝癌中嘌呤能受体X1的诊断价值  

Diagnostic Value of Purinergic Receptor X1 in Hepatocellular Carcinoma

作　　者：李朝 于运亮 LI Zhao;YU Yunliang(Department of Medical Laboratory,Linqing People′s Hospital,Linqing 252600,Shandong,China;Department of Medical Laboratory,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,Shandong,China)

机构地区：[1]临清市人民医院检验科,山东临清252600 [2]滨州医学院烟台附属医院检验科,山东烟台264100

出　　处：《医学信息》2025年第6期1-8,14,共9页Journal of Medical Information

基　　金：滨州医学院科研启动基金(编号:BY2019KJ43)。

摘　　要：目的探讨嘌呤能受体X1(P2RX1)的表达与肝细胞肝癌(LIHC)患者预后、肿瘤异质性及免疫浸润之间的关系。方法下载并处理癌症基因组图谱(TCGA)数据库关于P2RX1在LIHC中的表达谱数据及LIHC患者临床信息,分析P2RX1的表达与患者预后的关系;分析P2RX1的表达与LIHC等肿瘤异质性、肿瘤干性的关系;利用TIMER算法评估P2RX1与肿瘤免疫细胞浸润的相关性;分析P2RX1表达与8种免疫检查点(ICs)、免疫/基质评分、化疗药物半抑制浓度(IC_(50))等的相关性;对P2RX1不同表达组差异基因进行富集分析。结果P2RX1在LIHC中的表达下调(P<0.05)。P2RX1高表达的LIHC患者预后较好(P<0.05)。P2RX1的表达与LIHC肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)呈负相关(P<0.05)。P2RX1与LIHC患者性别、种族、TNM分期等无关。P2RX1与PD1、PD-L1等多个免疫检查点基因呈正相关,与顺铂、5-氟尿嘧啶等化疗药物的IC_(50)呈负相关(P<0.05)。富集分析结果显示,P2RX1广泛参与各种免疫细胞的增殖、激活、分化等生物学进程。结论P2RX1在多种消化系统肿瘤中表达下调,并与LIHC患者预后有关,参与LIHC肿瘤微环境免疫细胞增殖、分化、浸润等调控过程。Objective To investigate the relationship between the expression of purinergic receptor X1(P2RX1)and the prognosis,tumor heterogeneity and immune infiltration in patients with hepatocellular carcinoma(LIHC).Methods The expression profile data of P2RX1 in LIHC and the clinical information of LIHC patients in the Cancer Genome Atlas(TCGA)database were downloaded and processed,and the relationship between the expression of P2RX1 and the prognosis of patients was analyzed.The relationship between the expression of P2RX1 and tumor heterogeneity and tumor stemness such as LIHC was analyzed.The correlation between P2RX1 and tumor immune cell infiltration was evaluated by TIMER algorithm.The correlation between P2RX1 expression and 8 immune checkpoints(ICs),immune/matrix scores,and half-inhibitory concentration(IC_(50))of chemotherapeutic drugs was analyzed.Enrichment analysis of differentially expressed genes in different expression groups of P2RX1 was performed.Results The expression of P2RX1 was down-regulated in LIHC(P<0.05).The prognosis of LIHC patients with high expression of P2RX1 was better(P<0.05).The expression of P2RX1 was negatively correlated with LIHC tumor mutation burden(TMB)and microsatellite instability(MSI)(P<0.05).P2RX1 was not related to gender,race and TNM stage of LIHC patients.P2RX1 was positively correlated with multiple immune checkpoint genes such as PD1 and PD-L1,and negatively correlated with IC_(50) of chemotherapeutic drugs such as cisplatin and 5-fluorouracil(P<0.05).The results of enrichment analysis showed that P2RX1 was widely involved in the biological processes of proliferation,activation and differentiation of various immune cells.Conclusion The expression of P2RX1 is down-regulated in a variety of digestive system tumors and is related to the prognosis of LIHC patients.It is involved in the regulation of immune cell proliferation,differentiation and infiltration in the tumor microenvironment of LIHC.

关 键 词：嘌呤能受体X1 表达 预后 异质性 免疫浸润 

分 类 号：R735.7[医药卫生—肿瘤]